loading page

Diagnosis, Monitoring, and Management of Pyruvate Kinase Deficiency in Children
  • Shaniqua Johnson,
  • Rachael Grace,
  • Jenny Despotovic
Shaniqua Johnson
Texas Children's Hospital
Author Profile
Rachael Grace
Children's Hospital Boston / Dana-Farber Cancer Institute
Author Profile
Jenny Despotovic
Texas Children's Hospital
Author Profile

Abstract

Pyruvate kinase (PK) deficiency is an important cause of hereditary non-spherocytic hemolytic anemia caused by a defect in the glycolytic pathway in red blood cells. PK deficient erythrocytes have impaired ATP production and resultant difficulty maintaining normal cell integrity and function, leading to mild to severe anemia due to increased extravascular hemolysis and splenic destruction. Sequelae of chronic hemolysis can result in severe and occasionally life-threatening complications such as hepatobiliary disease, iron overload, bone and cardiopulmonary disease, as well as often markedly impaired quality of life. While the mainstay of management of PK deficiency involves supportive care, comprehensive screening recommendations and disease modifying therapies in development are likely to significantly improve the management of patients. Here, we provide a case-based comprehensive review of the diagnostic evaluation, complications, monitoring recommendations and management of PK deficiency in children.
06 Jul 2021Submission Checks Completed
06 Jul 2021Assigned to Editor
06 Jul 2021Submitted to Pediatric Blood & Cancer
07 Jul 2021Reviewer(s) Assigned
23 Jul 2021Review(s) Completed, Editorial Evaluation Pending
04 Aug 2021Editorial Decision: Revise Major
15 Nov 2021Assigned to Editor
15 Nov 2021Submission Checks Completed
15 Nov 20211st Revision Received
18 Nov 2021Reviewer(s) Assigned
29 Nov 2021Review(s) Completed, Editorial Evaluation Pending
29 Nov 2021Editorial Decision: Revise Minor
07 Feb 20222nd Revision Received
07 Feb 2022Submission Checks Completed
07 Feb 2022Assigned to Editor
08 Feb 2022Review(s) Completed, Editorial Evaluation Pending
08 Feb 2022Editorial Decision: Accept